Amgen (AMGN) Income from Continuing Operations (2009 - 2026)

Amgen has reported Income from Continuing Operations for 18 years, with the latest figure at $2.4 billion in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 65.85% year-over-year to $2.4 billion in Q2 2026; TTM through Jun 2026 was $8.7 billion, a 32.09% increase from a year earlier, with the FY2025 full-year figure at $7.7 billion, up 88.53% from the prior year.
• Income from Continuing Operations was $2.4 billion for Q2 2026 at Amgen, up from $1.8 billion in the prior quarter.
• The five-year high for Income from Continuing Operations was $3.2 billion in Q3 2025, with the low at -$113.0 million in Q1 2024.
• Average Income from Continuing Operations over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 103.98% in 2024, then soared 1630.97% in 2025.
• Over 5 years, Income from Continuing Operations stood at $1.6 billion in 2022, then sank by 52.54% to $767.0 million in 2023, then decreased by 18.25% to $627.0 million in 2024, then jumped by 112.6% to $1.3 billion in 2025, then surged by 78.17% to $2.4 billion in 2026.
• The last three Income from Continuing Operations figures came in at $2.4 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.